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Abstract
Pneumocystis pneumonia (PCP) is an opportunistic infection caused by the fungus Pneumocystis
jirovecii. Infection with P. jirovecii can result in serious illness in patients with a weakened immune
system, and can lead to death if it is not properly diagnosed and treated. Direct detection of P.
jirovecii in lower respiratory tract specimens such as bronchoalveolar lavage (BAL) is preferred for
rapid diagnosis, a laboratory service currently not available locally. We report here the development
of a diagnostic real-time Polymerase Chain Reaction (PCR) assay using BAL specimens to detect P.
jirovecii. By targeting the multi-copy mitochondrial large subunit ribosomal RNA gene (mtLSU rRNA)
of P. jirovecii, assay sensitivity is increased. Primer pairs were designed to include a fluorescent
reporter dye-labeled primer with a unique MultiCode® base pair isoC on the 5’end and one unlabeled
primer. The performance characteristics were determined on the Luminex ARIES® instrument,
combining DNA extraction, amplification and detection into a one-step process. The cassette contains
the reagents needed to perform all of the steps including extraction, purification, amplification, and
detection, plus a sample processing control. Accuracy, precision, sensitivity, specificity and stability
studies were conducted to validate the assay to meet CLIA requirements. The analytical sensitivity
was 89.1%, and the analytical specificity was 100%. The assay could reliably detect 200 organisms/
mL, crossing thresholds (Ct) and melt temperatures (Tm) were consistent, and no cross-reactivity
was observed with other pathogens known to cause respiratory infections. The results demonstrated
that these primers are specific to Pneumocystis jirovecii. The real-time PCR method using the
ARIES® system allowed for rapid and sensitive detection of Pneumocystis pneumonia infections with
P. jirovecii using clinical respiratory specimens.
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Introduction
Pneumocystis pneumonia (PCP) is a major health concern
for immunocompromised individuals, whether due to HIV
infection, chemotherapy or solid organ transplantation [1]. PCP
is caused by the opportunistic fungal pathogen Pneumocystis
jirovecii, a pathogen specific to humans, having no other
reservoir [2]. Individuals suffering from PCP usually present
with non-specific symptoms such as fever, cough, shortness of
breath, and fatigue. Sulfa drugs are the most common treatment
for infection [3].
A rapid and accurate laboratory test is important for early
diagnosis and treatment since any delay in treatment can
significantly increase the risk of mortality. This organism has
not been successfully cultured to date, so diagnosis depends
on other laboratory methods. Traditionally, PCP has been
diagnosed with the help of numerous staining methods or
fluorescent antibody assays. Detection of nucleic acids from P.
jirovecii in clinical samples has been evaluated numerous times,
with certain authors making the case that molecular detection,
such as quantitative PCR, should be the test of choice for PCP
[4, 5]. While concerns about colonized versus infected patients
have been raised, combining quantitative molecular detection
*Correspondence To: Leslie A. Wolf, PhD
Work Address: Infectious Diseases Laboratory, Division of Infectious Diseases,
Department of Medicine, University of Louisville, Louisville, Kentucky 40292 USA
Work Email: lawolf07@louisville.edu

with clinical judgment should reduce false positive results.
We developed and evaluated a real-time PCR assay to detect
P. jirovecii targeting mitochondrial large subunit ribosomal
RNA gene (mtLSU rRNA) in lower respiratory tract specimens
using the Luminex ARIES® instrument. The objective was to
provide a rapid and sensitive test to health care practitioners
serving immunocompromised patients in our area, since
sending these specimens to an out of state reference laboratory
is expensive and takes at least one week for results. The mtLSU
rRNA target was chosen because of the copy number and
previous comparative studies [6]. The Luminex ARIES® is an
open-platform instrument which uses MultiCode-RTx® base
pairing (isoC:isoG) technology. This instrument was selected
because it simplifies the extraction, amplification and detection
process without affecting the robustness of diagnostic testing.
Selective primers, labeled with fluorescent dyes, facilitate real
time detection of both the mtLSU rRNA gene target for PCP and
an internal control in a single-step. This assay enables rapid
diagnosis with great sensitivity and specificity with little handson time required.
Copyright: © 2019 The author(s). This is an open access article distributed under
the terms of the Creative Commons Attribution 4.0 International License (CC BY
4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.

Materials and Methods

Table 2 PCR Thermal profile used for Luminex ARIES® P. jirovecii PCR
assay.

Specimens
Archived, de-identified PCP positive and negative clinical
specimens were provided by Dr. Scott McClellan, University of
Michigan, in order to set assay parameters. These specimens
were deemed exempt by the University of Michigan Institutional
Review Board (S. McClellan, personal communication). Residual
BAL specimens from consenting patients were used for analytical
sensitivity, accuracy, precision, stability and specificity studies.
Residual BAL specimens were determined to be negative for P.
jirovecii using this PCR method prior to spiking with known
concentrations of P. jirovecii DNA. Briefly, specimen processing
was done in Bertin tubes (Precellys Lysis Kit, Reference number
KT03961-1-006.2, Bertin Corp, Rockville, MD). First, 400 μl of
BAL sample were added to the Bertin tube with 400 μL of AL
buffer (QIAGEN Catalog number: 19075, Germantown, MS).
The Bertin tube was placed on a vortex adaptor and shaken at
10,000 rpm for 5 minutes to disrupt cells. After incubating at
room temperature for 10 minutes, the tubes were centrifuged
for 2 minutes at 14,000 rpm. Finally, 400 μL of supernatant was
added to tubes containing 5 μL of carrier RNA, vortexed, then
405 μL of sample with carrier RNA was used for the assay.
Organisms
Fungal isolates were provided by Dr. Alan Junkins, Norton
Healthcare, Louisville, KY. Eleven different fungi were spiked
into negative BAL specimens and tested to assess cross-reactivity
as follows: Candida dubliniensis, Candida parapsilosis,
Candida glabrata, Candida krusei, Candida tropicalis,
Cryptococcus
neoformans,
Saccharomyces
cerevisiae,
Histoplasma capsulatum (yeast form), Aspergillus fumigatus,
Aspergillus versicolor and Aspergillus niger. Streptococcus
pneumoniae isolates from the University of Louisville Infectious
Diseases Laboratory were tested in the same way to assess
cross-reactivity. A single colony was selected from freshly subcultured plates using a sterile calibrated loop; the loop was used
to inoculate BAL from patient specimens previously determined
to be negative for PCP processed as described in the specimen
section. College of American Pathologists (CAP) proficiency
testing samples (archived IDR-A and IDR-B from 2018 events)
containing numerous respiratory viruses and bacteria were used
to assess cross-reactivity. For that purpose, 200 μL of proficiency
test samples known to contain the following were spiked into
negative BAL specimens: Coxsackie virus A9, Chlamydophila
pneumoniae strain CWL 029, Influenza A California 07/2009
(H1N1), Bordetella pertussis A639, Influenza B Massachusetts
2/2012, Coronavirus NL63, Parainfluenza Type 2, RSV Type B
CH93(18)-18, Bordetella parapertussis A747, Parainfluenza
virus Type 4, Echovirus 30 (E-30), Influenza B Strain
Brisbane 60/2008, Parainfluenza Type 3, Adenovirus Type 21,
Mycoplasma pneumoniae M129, Influenza A strain New York
18/2009 (H1N1), and Human metapneumovirus B2. Also,
previously characterized bacterial stocks from the University
of Louisville Infectious Diseases Laboratory were tested to
assess cross-reactivity [7]. Chlamydia pneumoniae, Legionella
pneumophila, and Mycoplasma pneumoniae from each
bacterial stock were spiked into BAL, using 160 μL of 1x105 CFU/
mL stock as input.
Forward Primer Reverse Primer Gene Target

Pneumocystis
jirovecii

5’-CAG ACT
ATG TGC GAT
AAG GTA GAT
AGT CG-3’

5’-/56FAM/iMeisodC/GGA GCT
TTA ATT ACT
GTT CTG GGC-3’

Mitochondrial
large subunit
ribosomal RNA
gene

Amplicon Length
(bp)
64

95C
0 sec
95C
120 sec
95C
5 sec
62C
7 sec
72C
14 sec
3 (from Denature to Extend)
Extension
45
0.5C
60C
95C
2 sec
Melt hold time

Control Materials
Due to the limited number of clinical samples available
for testing, recombinant P. jirovecii positive controls were
purchased from Zeptometrix (NATtrol P. jirovecii Recombinant
External Run Control, Catalog number 320679, Buffalo, NY)
and EXACT Diagnostics (custom Pneumocystis jirovecii run
control, Reference number PCPRC, Fort Worth, TX).
Reagents
ARIES® MultiCode® DNA ReadyMix® tubes (Part number:
3697, Luminex, Austin, TX) and ARIES® extraction cassettes
(Part number: 50-10026, Luminex) were purchased ready to
use. Carrier RNA (QIAGEN part number 1017647, Germantown,
MD) was prepared as a 1 μg/μL solution in AVE buffer (QIAGEN
part number 1026956, Germantown, MD), aliquots were
stored at -20°C. Primer pairs, obtained from Integrated DNA
Technologies Inc. (IDT, Coralville, IA), were designed to include
a FAM reporter-labeled reverse primer with an isodC on the
5’end, and a second unlabeled forward primer for P. jirovecii.
The primer set was designed to amplify the mitochondria large
subunit (mtLSU) rRNA from P. jirovecii based on a previous
study [8]. Primer designs were evaluated by eye, then screened
using IDT’s Oligo Analyzer software. Primer sequences are
shown in Table 1. Each primer was used at a final concentration
of 200 nM. Mouse Hepatitis Virus 2 control primers (MHV2,
proprietary, Luminex Part Number 3803, Austin, TX) were
used to amplify the Sample Processing Control (SPC; confirms
extraction, amplification and detects inhibition). The SPC
calibrator function allowed for calibration of detected melting
temperatures (Tm) based on MHV2 amplification.
Primer Pool Preparation
The mtLSU rRNA forward and reverse lyophilized primers were
dissolved in Tris-EDTA (TE buffer, Fisher Catalog #BP2473-1,
Waltham, MA) to make a 100 μM stock solution of each primer.
Further dilution of the 100 μM stock was done with molecular
grade water to make 5 μM working stock. To prepare the pooled
primer mix, 100 μL of each 5 μM stock primer was combined
with 100μL of MHV2 primer stock to make 300 μL total volume.
Table 3 P. jirovecii assay Amplification and Melt Curve Settings for ARIES®
Setting

Table 1 Primers used for Luminex ARIES® P. jirovecii PCR assay.
Organism

PCR
Pre-heat Temperature
Pre-heat hold time
Activation Temperature
Activation Time
Denature Temperature
Denature Time
Anneal Temperature
Anneal hold Time
Extension Temperature
Extension hold Time
Number of PCR steps repeat
Optical Read Location
Number of PCR cycles
Melt
Melt Temperature Step
Melt Start Temperature
Melt final Temperature
Melt Hold Time
Optical read location

Conditions

P. jirovecii
mtLSU rRNA target
FAM channel

SPC
MHV2 target
AP525 channel

Amplification curve
Cut off (Ct)
1-40
1-45
Melt curve (Tm)
77.4-78.9
74.7-79.7
2
Cutoff (C)
(78.150.75)
(77.22.5)
Melt curve (Tm) Peak
3
-700,000
-150,000
Threshold cutoff (RFU)
SPC= Sample Processing Control; RFU=Change in relative fluorescent units
1
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Table 4 Assay Sensitivity for P. jirovecii in BAL Specimens
Concentration
P. jirovecii mtLSU
P. jirovecii
SPC
(~Number
rRNA
mtLSU rRNA
MHV2
organisms/mL
Ct values (SD)
Tm values (SD)
Ct values (SD)
in BAL)
5
2x10
25.97 (0.45)
77.90 (0.00)
34.23 (1.06)
2x104
30.50 (0.82)
78.00 (0.00)
34.43 (0.80)
2x103
33.87 (0.29)
78.03 (0.06)
33.73 (0.83)
2x102
37.57 (1.04)
77.97 (0.15)
33.83 (1.12)
2x101
ND
ND
34.87 (1.37)
0
*
*
2x10
38.10
78.00
35.03 (0.97)
SPC= Sample Processing Control ;ND=Not Detected; SD= Standard Deviation
*Positive result in one out of three runs.

Table 6A Intra-assay Precision Studies for the P. jirovecii PCR Assay

SPC
MHV2
Tm values( SD)
77.40 (0.26)
77.37 (0.32)
77.40 (0.30)
77.37 (0.32)
77.53 (0.31)
77.40 (0.17)

ARIES® Cassette and Instrument Preparation
Six (6) µL of the mtLSU rRNA pooled primer mix were added
to each MultiCode® DNA ReadyMix® tube, then attached to the
ARIES® cassette. ARIES® Cassettes (Part Number: 50-10026,
Luminex, Austin, TX) contained the extraction reagents. Four
hundred (400) µL of processed BAL sample were added to a 1.5
mL micro centrifuge tube along with 5 µL of a 1 µg/mL carrier
RNA stock. The tube was vortexed for five seconds prior to
transferring the entire volume to the cassette and loaded onto
the ARIES® instrument. The extraction, PCR reaction and result
generation then proceeded automatically (PCR thermal cycle
profile in Table 2).
Sensitivity
For analytical sensitivity, the LOD was determined for the
mtLSU rRNA target in BAL specimens that were negative by the
Luminex ARIES® PCR assay described here. The Zeptometrix
PCP positive control (400 µL, 2x105 organisms per mL) was
used as the initial dilution, followed by 6 ten-fold dilutions in
the negative BAL specimen, then tested as described above. The
LOD assay was conducted three times independently (Table 4).
Accuracy
A panel of 24 (18 BAL, five sputum and one induced sputum)
previously known positive and ten (eight BAL, one bronchial
wash, and one sputum) known negative patient specimens
provided by Dr. Scott McClellan (University of Michigan) were
tested. Additionally, 17 spiked positive samples [PCP controls
at varying dilutions: nine Zeptometrix controls at 2x105, 2x104,
2x103, 2x102 organisms per mL, and eight Exact Diagnostics
controls at 125,000 copies/mL, 12,500 copies/mL, 1250 copies/
mL and 125 copies/mL in BAL (Table 5)] and 14 negative
blinded BAL samples were also tested by different technologists.
Precision
Reproducibility studies to determine precision were conducted
using the Zeptometrix PCP control diluted 1:100 (2x103
organisms/mL) in negative BAL samples. To demonstrate
intra-assay and inter-assay precision, positive controls were
tested for seven days and negative controls were tested for five
days in duplicate, then for 10-15 days in singlet using different
technologists. Average and standard deviations were calculated
using MS Excel (Table 6, A&B).
Table 5 Accuracy Results for the P. jirovecii PCR Assay

Positive
(clinical and
spiked
respiratory
specimens)
PCP Negative
(clinical
respiratory
specimens)

Positive
Control 1
Positive
Control 2
Average (SD)
Sample Type

The complete primer pool was then mixed well by vortexing,
spun down and stored in 60 μL aliquots at -20°C.

P. jirovecii

Sample Type

Negative
Control 1
Negative
Control 2
Average (SD)

Day
1 Day
2 Day
3 Day
4 Day
5 Day
6 Day
7
mtLSU
mtLSU
mtLSU
mtLSU
mtLSU
mtLSU
mtLSU
rRNA Ct rRNA Ct rRNA Ct rRNA Ct rRNA Ct rRNA Ct rRNA Ct
value
value
value
value
value
value
value
30.7
31.4
33.8
34.10
32.7
33.6
32.8
32.7

31.9

32.1

31.6

32.2

34.5

33.7

31.7
31.65
32.95
32.85
32.45
34.05
(1.41)
(0.35)
(1.2)
(1.77)
(0.35)
(0.64)
Day
1 Day
2 Day
3 Day
4 Day
5 Day 6 SPC
SPC
Ct SPC
Ct SPC
Ct SPC
Ct SPC
Ct Ct value
value
value
value
value
value
33.6
37.2
37.8
37.0
35.3
N/A

33.25
(0.64)
Day
7
SPC Ct
value
N/A

33.0

38

40.1

37.4

36.3

N/A

N/A

33.3
(0.42)

37.6
(0.56)

38.95
(1.62)

37.2
(0.28)

35.8
(0.70)

N/A

N/A

Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected;
SPC=Sample Processing Control; N/A=Not Applicable

Table 6B Inter-assay Precision Studies for the P. jirovecii PCR Assay

Sample Type

P. jirovecii mtLSU P. jirovecii Tm SPC Ct value
SPC Tm value
rRNA Ct value
value
Positive Control 32.98 (0.91)
77.98 (0.12)
35.02 (1.75)
76.99 (0.32)
(n=15)
Negative Control ND
ND
36.12 (1.72)
77.28 (0.36)
(n=10)
Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected;
SPC=Sample Processing Control

Stability
Specimen stability studies were conducted by incubation of
negative BAL samples spiked with known PCP Zeptometrix
positive control diluted 1:100 (2x103 organisms/mL) and stored
at 4°C, then assayed daily for 8 days (Table 7A). In addition,
nine different known P. jirovecii positive clinical BAL samples
were pooled and stored at 4°C, then assayed daily for 8 days
(Table 7B).
Specificity
Eleven different fungi, eight different bacteria and 13 different
viruses were spiked into negative BAL and tested in to assess
cross-reactivity (Table 8).
Data Analysis
Microsoft Excel® was used to calculate standard deviations
for replicate experiments, while MedCalc Diagnostic Test
Evaluation was used to determine analytic sensitivity and
specificity [9]. The User Defined Protocol (UDP) module in
the SYNCT® software was used to set assay parameters. The
SYNCT® software was installed on an external computer for
Table 7A P. jirovecii Stability Studies using positive control spiked into
negative BAL
Specimen
Type
BAL

P.jirovecii
mtLSU rRNA Ct
Average (SD)
33.24 (0.57)

P. jirovecii
SPC Ct Average
mtLSU rRNA Tm (SD)
Average (SD)
78.04 (0.09)
34.29 (1.34)

SPC Tm Average
(SD)
76.95 (0.24)

Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected;
SPC=Sample Processing Control

Table 7B P. jirovecii Stability Studies using pooled clinical P. jirovecii
positive BAL

Expected
Positive

Observed
Positive

%
Agreement

% Sensitivity
(95% Confidence Interval)

% Specificity
(95% Confidence Interval)

41

36

87.8

89.13 (76.43-96.38)

N/A

0

0

100

N/A

100 (85.75-100)

Specimen
Type
BAL

P.jirovecii
P. jirovecii
mtLSU rRNA Ct mtLSU rRNA
Average (SD)
Tm Average
(SD)
34.46 (0.50)
77.93 (0.08)

SPC Ct Average
(SD)

SPC Tm Average
(SD)

37.86 (2.20)

77.56 (0.13)

Ct=Cycle threshold; Tm=Melt temperature; ND=Not Detected;
SPC=Sample Processing Control

N/A=Not applicable
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Table 8 Specificity Studies for the P. jirovecii PCR assay
Organism

Candida dubliniensis
Candida parapsilosis
Candida glabrata
Candida krusei
Candida tropicalis
Cryptococcus neoformans
Saccharomyces cerevisiae
Histoplasma capsulatum (yeast form)
Aspergillus fumigatus
Aspergillus versicolor
Aspergillus niger

Fungi

Bacteria
Chlamydophila pneumoniae strain CWL 029
Bordetella pertussis A639
Bordetella parapertussis A747
Mycoplasma pneumoniae strain M129
Chlamydia pneumoniae
Legionella pneumophila
Mycoplasma pneumoniae
Streptococcus pneumoniae
Viruses
Enterovirus Coxsackie A9
Influenza A strain California 07/2009 (H1N1)
Influenza B Massachusetts 2/2012
Coronavirus NL63
Parainfluenza Type 2
RSV Type B CH93 (18)
Parainfluenza virus Type 4
Echovirus 30 (E-30)
Influenza B Strain Brisbane 60/2008
Parainfluenza Type 3
Adenovirus strain Type 21
Influenza A strain New York 18/2009 (H1N1)
Human metapneumovirus strain B2

Matrix SPC Ct SPC
PCR Results
Value Tm
for
P.
Value jirovecii
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL

32.4
33.9
34.9
33.9
35.1
33.3
32.8
33.9
34.7
36.1
32.1

76.6
76.9
76.9
76.9
76.9
77.1
77.7
76.9
76.6
76.4
76.9

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL

36.5
37.5
37.6
39.4
39.3
38.2
36.9
39.1

77
77.1
76.8
76.9
76.9
76.7
76.9
77.7

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL
BAL

36.5
37.5
35.9
35.9
37.6
37.6
37.6
36.7
39.5
39.5
39.4
39.7
39.7

77
77.1
76.9
76.9
77
77
76.8
77.1
76.9
76.9
76.9
76.9
76.9

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

detailed data analysis and editing of Ct and Tm cutoff values.
After completing data analysis and PCR assay validation, the
Ct and Tm cut off values were set and locked in the SYNCT®
software assay file. Next, the assay file was loaded on the ARIES®
instrument for subsequent diagnostic laboratory testing (Table
3). In order for a specimen to be called positive for P. jirovecii,
the following conditions had to be met:
1.
The SPC for any negative specimen must have a valid Ct
value and Tm to exclude sample inhibition.
2. The specimen must have Ct and Tm values in the
established range for the target organism P. jirovecii.

The assay could reliably detect 3000 copies of mtLSU rRNA
that equated to 200 organisms/mL of P. jirovecii (Table 4) in
respiratory specimens. It is important to note that P. jirovecii is
estimated to have 15 copies of the mtLSU rRNA gene/organism
[10], allowing for more sensitive detection by PCR.

Discussion
Quality laboratory results are dependent on proper specimen
collection, transport, storage and processing procedures, as well
as adherence to good molecular laboratory techniques to avoid
false positive and false negative results. As with any laboratory
test, regardless of the method used to diagnose Pneumocystis
pneumonia, clinical judgment in light of patient presentation
and history are the ultimate deciding factors for patient
treatment and management [11].
The strengths of this study include the demonstration of the
precision, limit of detection using quantitated target DNA and
demonstration of specificity. In addition, the ability to adapt the
PCR assay to the Luminex ARIES® platform so that extraction,
amplification and detection occur in a closed system reduces
potential cross-contamination. Some limitations of this study
include the small number of clinical samples available for testing
and the use of spiked BAL samples to mimic clinical samples.
Due to a limited number of available clinical specimens,
stability studies were conducted with positive control material
in the form of plasmids as well as with pooled positive clinical

Results
Using a combination of positive and negative patient specimens,
and spiked known concentrations of recombinant external
positive controls, the performance characteristics of the PCR
assay on the ARIES® system were established. The results of
this study were highly reproducible, as demonstrated by testing
positive and negative controls with different technologists
on different days. We obtained consistent results with low
standard deviations (Tables 4, 6A&B and 7A&B). Analytical
sensitivity for the P. jirovecii assay was 89.1% (95% CI 76.4396.38%), while analytical specificity was 100% (95% CI 87.23
-100), (Table 5). Stability studies were performed using
positive control material spiked into negative BAL and pooled
P. jirovecii clinical positive BAL samples, stored at 2-8°C for
eight days and tested daily for 8 days. Results showed that DNA
was detected by the PCR assay under these storage conditions
(Table 7A and B). Finally, a variety of fungi, bacteria, and
viruses that can cause respiratory infections were tested to
establish specificity. There was no cross-reactivity observed
with the P. jirovecii mtLSU rRNA primers using 32 different
organisms (Table 8). By including the SPC, any inhibition of
PCR would have been detected, and none was observed during
these studies (Table 8).

Figure 1A Negative Control Result: Sample data from ARIES® instrument
with a negative control illustrating the amplification curve (Ct) and melt
temperature (Tm) for the internal control (SPC).

Figure 1B Positive Control Result: Sample data from ARIES® instrument
with a positive control illustrating the amplification curve (Ct) and melt
temperature (Tm) for P. jirovecii.
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specimens. Comparison to a “gold standard” assay was also
problematic. Numerous publications regarding PCR detection
of P. jirovecii have used a wide variety of gene targets, methods,
instruments, and limits of detection reporting units (i.e. trophic
form equivalents [12], plasmid copy/uL [13], DNA copy/uL
[11] or cysts/amplification [14], making direct comparisons
challenging [15]).
A valid concern with PCP molecular detection assays is that this
PCR assay could detect colonized patients as well as patients
with infections. While this PCR assay was used in a qualitative
manner, the Ct values provided some indication of organism
load when P. jirovecii was detected [12, 13]. Example instrument
results are provided in Figures 1A and 1B. Based on a likely
human-to-human transmission route [16-18], detecting
colonization may be relevant in certain situations. Setting a
cutoff for colonization may not be practical for all situations,
however, such as fungal load variability in HIV-infected versus
non-infected immunosuppressed patients, or pediatric patients
versus adult patients [8, 11, 19]. While microscopic analysis
remains a valid laboratory method for determining infection
with these organisms, it requires a high level of technical
expertise. It also lacks the sensitivity of molecular diagnostics
by an estimated factor of 100 [14], thus supporting the need for
molecular diagnostic assays for detection of P. jirovecii.
Exploration of quantitative PCR assays for P. jirovecii, adding
other targets (e.g. drug resistance markers or virulence factors),
and identifying other high copy number genes such as the
mitochondrial smaller subunit (mtSSU) rRNA [10] are future
goals to make this assay more sensitive and useful to clinicians.
In particular, drug resistance markers are of great interest in
an era of antibiotic stewardship initiatives. A study conducted
in Chile observed a high prevalence of mutations in the
dihydropteroate synthase (DHPS) gene in P. jirovecii infected
patients, despite a lack of previous exposure to trimethoprimsulfamethoxazole or dapsone [18]. This study suggested a role
for person-to-person transmission. The presence of the DHPS
mutation correlated with twice longer duration of mechanical
ventilation in this hospitalized group of 56 patients [18],
indicating an important area for future study.
The benefits of the ARIES® P. jirovecii assay include minimal
hands-on time for technologists, one step specimen processing
with a robust internal sample processing control, all within
a closed system. Results are available within two hours while
providing rapid, specific and sensitive results for health care
providers. The ability to tailor PCR assays to the local health
care community, and to add new targets with guidance from
Luminex technical support, adds a high degree of flexibility
for future P. jirovecii assay improvements. Based on the
performance characteristics established by our laboratory, the
ARIES® real-time PCR assay meets the CLIA requirements for
diagnostic testing using BAL specimens from patients suspected
of having PCP. Having the real-time PCR assay available to
health care providers managing immunocompromised patients
in our community will provide results within 24 hours of receipt,
leading to better patient management.
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